We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alligator Bioscience Ab | LSE:0RK9 | London | Ordinary Share | SE0000767188 | ALLIGATOR BIOSCIENCE ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 61.9M | -248.59M | -1.1221 | -20.50 | 5.1B |
STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- "Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile with only minor drug-related side effects."
- Per Norlén, CEO Alligator Bioscience
SIGNIFICANT EVENTS OCTOBER-DECEMBER
Mitazalimab:
ATOR-1017:
ALG.APV-527:
Other:
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD
FINANCIAL SUMMARY
October-December 2020
January-December 2020
During the first quarter, the holdings in corporate bonds and interest funds were divested, which had a positive effect on cash flow.
The full report is attached as PDF available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/
Conference call/webcast
Alligator will host a conference call today, February 26, 2021, at 2:00 p.m. CEST for investors, analysts and media, where CEO Per Norlén and CFO Marie Svensson will present and comment on the Year-end Report. The conference will be held in English.
The conference call will be broadcast live on the web via the link:
https://tv.streamfabriken.com/alligator-bioscience-q4-2020
Telephone number for the conference call is:
SE: +46850558358
UK: +443333009266
US: +18335268382
For further information, please contact:
Per Norlén, CEO
E-mail: per.norlen@alligatorbioscience.com
Phone: +46 46 540 82 00
Marie Svensson, CFO
E-mail: marie.svensson@alligatorbioscience.com
Phone: +46 46 540 82 03
The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 a.m. CET on February 26, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com..
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--year-end-report-january-december-2020,c3296041
The following files are available for download:
https://mb.cision.com/Main/12681/3296041/1379295.pdf | Alligator Bioscience AB: Year-end Report January-December 2020 |
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-year-end-report-january-december-2020-301236304.html
SOURCE Alligator Bioscience
Copyright 2021 PR Newswire
1 Year Alligator Bioscience Ab Chart |
1 Month Alligator Bioscience Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions